Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Sonic: Escalated inpatient ramp-up of sonrotoclax in CLL/SLL and MCL

Jennifer Huang, Laura Samples, Ted Gooley, Margo Fredericks, Stephanie Louie, Grace Bishop, Christine Crider, Mehrdad Azar, Neena Kennedy, Mengyang Di, Stephen Smith, Brian Till, Ajay Gopal, Ryan Lynch, Chaitra Ujjani, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 2136.

https://doi.org/10.1182/blood-2025-2136

Published: 2025

Journal Articles

SGR-1505, a potent and selective MALT1 inhibitor with preliminary efficacy in BTKi exposed Waldenström macroglobulinemia (WM) and “double-exposed” CLL/SLL

Blood (2025) 146 (Supplement 1): 3603.

https://doi.org/10.1182/blood-2025-3603

Published: 2025

Journal Articles

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

Ryan Lynch, Christina Poh, Mazyar Shadman, Brian Till, Mengyang Di, Chaitra Ujjani, Vikram Raghunathan, Stephen Smith, David Maloney, Daria Gausman, Heather Rasmussen, David Russler-Germain, Todd Fehniger, David Kurtz, Ash Alizadeh, Jenna Voutsinas, Ajay Gopal

Blood (2025) 146 (Supplement 1): 3591.

https://doi.org/10.1182/blood-2025-3591

Published: 2025

Journal Articles

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Blood (2025) 146 (Supplement 1): 1841.

https://doi.org/10.1182/blood-2025-1841

Published: 2025

Journal Articles

Evaluation of real-world outcomes with zanubrutinib in patients with marginal zone lymphoma: Results from multicenter cohort study

Narendranath Epperla, Geoffrey Shouse, Jess Hatfield, Kanithra Sekaran, Yun Choi, Aishwarya Sannareddy, Bryce Bowler, Zain El-amir, Ly Do, Matthew Savas, Taylor Kujawa, Priyanka Pophali, Yasmin Karimi, Mengyang Di, Praveen Ramakrishnan Geethakumari, Yazeed Sawalha, Reem Karmali, Natalie Grover, Adam Olszewski

Blood (2025) 146 (Supplement 1): 4534.

https://doi.org/10.1182/blood-2025-4534

Published: 2025

Journal Articles

Causes of death in chronic lymphocytic leukemia/small lymphocytic lymphoma during the novel agent era: A population-based analysis

Mengyang Di, Scott Huntington, Jenna Voutsinas, Qian Wu, Scott Ramsey, Jennifer Huang, Ajay Gopal, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 4520.

https://doi.org/10.1182/blood-2025-4520

Published: 2025

Journal Articles

Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma

Mengyang Di, Qian Wu, Ryan Lynch, Stephen Smith, Mazyar Shadman, Paul Martin, Brian Till, Neena Kennedy, Chaitra Ujjani, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5394.

https://doi.org/10.1182/blood-2025-5394

Published: 2025

Journal Articles

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

Blood (2025) 146 (Supplement 1): 3622.

https://doi.org/10.1182/blood-2025-3622

Published: 2025

Journal Articles

Changes in real-world treatment patterns over time by patient characteristics and time burden of treatment in CLL/SLL

Mengyang Di, Xiaoliang Wang, Qianhong Fu, Dong Yuan, Gregory Maglinte, Erlene Seymour, Joanna Rhodes

Blood (2025) 146 (Supplement 1): 6283.

https://doi.org/10.1182/blood-2025-6283

Published: 2025

Journal Articles

Real-world barriers to treatment access in T-cell lymphoma

Bryce Bowler, Jenna Voutsinas, Qian Wu, Maya Krishnan, Dhruv Mistry, Grace Sun, Mazyar Shadman, Brian Till, Ryan Lynch, Vikram Raghunathan, Chaitra Ujjani, Stephen Smith, Mengyang Di, Paul Martin, Ajay Gopal, Christina Poh

Blood (2025) 146 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2025-4491

Published: 2025

Journal Articles

Differences in patient-reported time toxicity between bispecific antibody (BsAb) options: Impact of treatment duration and dosing frequency on patient-reported time burden in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

Ajay Major, Esprit Ma, Anthony Masaquel, Mazie Tsang, Mengyang Di, Supreet Kaur, Priyanka Pophali, Sally Werner, Rebecca Bungay, Dominick Latremouille-Viau, Annie Guerin, Carolina Reyes, Mei Wu, Lourenia Cassoli, Pallawi Torka

Blood (2025) 146 (Supplement 1): 6181.

https://doi.org/10.1182/blood-2025-6181

Published: 2025

Journal Articles

End points and outcomes in follicular lymphoma: what should we measure, how, and why?

Mengyang Di, Matthew J. Maurer, Christopher R. Flowers

Blood (2025) 146 (15): 1802–1811.

https://doi.org/10.1182/blood.2024026978

Published: 2025

Journal Articles

Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

Blood (2025) 145 (23): 2762–2767.

https://doi.org/10.1182/blood.2024026831

Published: 2025

Includes: Supplemental data

Journal Articles

A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress

Carrie I Ho, Mengyang Di, Ryan C Lynch, Christina Poh, Vikram Raghunathan, Mazyar Shadman, Stephen D. Smith, Brian G. Till, Paul S Martin, Chaitra S. Ujjani, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 1661.2.

https://doi.org/10.1182/blood-2024-204154

Published: 2024

Journal Articles

Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)

Tycel Phillips, Mengyang Di, Taavy Miller, Jingru Wang, Amy Pierre, Gregory A. Maglinte, Erlene Kuizon Seymour, Yucai Wang

Blood (2024) 144 (Supplement 1): 3732.

https://doi.org/10.1182/blood-2024-208063

Published: 2024

Journal Articles

Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia

Christina Poh, Xueyan Chen, Jenna M. Voutsinas, Edus H. Warren, Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Vicky Wu, Sindhu Cherian, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 3069.

https://doi.org/10.1182/blood-2024-205892

Published: 2024

Journal Articles

Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma

Mengyang Di, Carrie I Ho, Stephen D. Smith, Mazyar Shadman, Chaitra S. Ujjani, Ryan C. Lynch, Christina Poh, Vikram Raghunathan, Brian G. Till, Edus H. Warren, Ajay K. Gopal, Stephanie J. Lee

Blood (2024) 144 (Supplement 1): 5116.

https://doi.org/10.1182/blood-2024-201827

Published: 2024

Journal Articles

Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial

Jennifer J. Huang, Laura Samples, Margie Fredericks, Stephanie Louie, Ramya Pulluru, Christine Crider, Mehrdad Shakib-Azar, Neena Kennedy, Vikram Raghunathan, Christina Poh, Mengyang Di, Stephen D. Smith, Brian G. Till, Ajay K. Gopal, Chaitra S. Ujjani, Ryan C. Lynch, Mazyar Shadman

Blood (2024) 144 (Supplement 1): 4634.2.

https://doi.org/10.1182/blood-2024-204491

Published: 2024

Journal Articles

Real-World Blood Counts in Patients Treated with Venetoclax for Relapsed or Refractory CLL/SLL

Laura Samples, Sirin Khajaviyan, Sara Keshmiri, Ryan S. Basom, Ryan C Lynch, Vikram Raghunathan, Mengyang Di, Mehrdad Shakib-Azar, Christine Crider, Margie Fredericks, Christina Poh, Stephanie Louie, Stephen D. Smith, Brian G. Till, Ajay K. Gopal, Chaitra S. Ujjani, Mazyar Shadman

Blood (2024) 144 (Supplement 1): 6785.

https://doi.org/10.1182/blood-2024-211971

Published: 2024

Journal Articles

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Blood (2024) 144 (Supplement 1): 6451.

https://doi.org/10.1182/blood-2024-194844

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Sonic: Escalated inpatient ramp-up of sonrotoclax in CLL/SLL and MCL

SGR-1505, a potent and selective MALT1 inhibitor with preliminary efficacy in BTKi exposed Waldenström macroglobulinemia (WM) and “double-exposed” CLL/SLL

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Evaluation of real-world outcomes with zanubrutinib in patients with marginal zone lymphoma: Results from multicenter cohort study

Causes of death in chronic lymphocytic leukemia/small lymphocytic lymphoma during the novel agent era: A population-based analysis

Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

Changes in real-world treatment patterns over time by patient characteristics and time burden of treatment in CLL/SLL

Real-world barriers to treatment access in T-cell lymphoma

Differences in patient-reported time toxicity between bispecific antibody (BsAb) options: Impact of treatment duration and dosing frequency on patient-reported time burden in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

End points and outcomes in follicular lymphoma: what should we measure, how, and why?

Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress

Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)

Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia

Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma

Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial

Real-World Blood Counts in Patients Treated with Venetoclax for Relapsed or Refractory CLL/SLL

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only